Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 8/20 | 0.52 |
| ▸ | APOB | P04114 | 7/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.49 |
| ▸ | SMO | Q99835 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | UGCG | Q16739 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6791861 | 0.89 | PTGS1 (0.51) | MTTPAPOBSMOPTGS1SMN1; SMN2 | |
| SCHEMBL6793635 | 0.89 | MTTP (0.51) | MTTPAPOBNR3C1SMOKDM4E | |
| SCHEMBL6792150 | 0.86 | MTTP (0.49) | MTTPAPOBNR3C1SMOUGCG | |
| SCHEMBL6788368 | 0.85 | SMO (0.61) | MTTPAPOBNR3C1SMOPTGS1 | |
| SCHEMBL6794470 | 0.85 | TP53 (0.54) | MTTPAPOBSMOKDM4ESMN1; SMN2 | |
| SCHEMBL6799011 | 0.82 | PTGS1 (0.47) | MTTPAPOBSMOPTGS1SMN1; SMN2 | |
| SCHEMBL6493011 | 0.81 | MTTP (0.48) | MTTPAPOBSMOPTGS1TP53 | |
| SCHEMBL6789124 | 0.81 | TP53 (0.50) | MTTPAPOBSMOKDM4ESMN1; SMN2 | |
| SCHEMBL6503526 | 0.81 | TRPV1 (0.43) | MTTPAPOBSMOPTGS1TP53 | |
| SCHEMBL6800432 | 0.81 | L3MBTL1 (0.46) | SMN1; SMN2TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | MTTP 363/4885APOB 1/4885NR3C1 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.